copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Entasis Appoints Mike Gutch as Chief Financial Officer and Chief . . . WALTHAM, Mass — April 10, 2017 — Entasis Therapeutics Inc , a company focused on the discovery and development of breakthrough anti-infective products, today announced the appointment of Mike Gutch, Ph D , as Chief Financial Officer and Chief Business Officer
Presentation - entasistx. com Background Multidrug resistant (MDR) Acinetobacter baumannii infections are of great concern due to high mortality rates and limited number of treatment options b-lactamase (BLA) expression, especially Class D, is an important resistance mechanism in this organism The novel BLA inhibitor ETX2514 has potent activity against Class A, C and D serine BLAs The MIC90 of sulbactam (SUL) in the
Entasis Therapeutics Entasis Therapeutics Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections